NewVale Capital
Overview
NewVale Capital is a growth equity investment firm founded in 2022 that focuses on supporting the services architecture of the life science industry. The firm invests in proven, revenue-generating services, software, and technology businesses across the pharmaceutical value chain, including discovery, clinical, manufacturing, and commercialization. It aims to invest in companies that help accelerate timelines, reduce costs, and improve quality in bringing new medicines to patients.
Portfolio Companies
4
Website
newvalecapital.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Aizon | Feb 2024 | Series C | Lead |
| Argonaut Manufacturing Services | Mar 2024 | Series A | Lead |
| Noxilizer | Sep 2025 | Growth Equity | Lead |
| Beaconcure | Jun 2023 | Series B | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is NewVale Capital based?
NewVale Capital is headquartered in Boulder, Colorado, United States.
When was NewVale Capital founded?
Founding year information for NewVale Capital is not publicly available.
How many portfolio companies does NewVale Capital have?
NewVale Capital has 4 portfolio companies in Caplight's dataset.
What are some companies in NewVale Capital's portfolio?
Portfolio companies visible on Caplight include Aizon, Argonaut Manufacturing Services, Noxilizer, Beaconcure.
What was NewVale Capital's most recent investment shown here?
NewVale Capital's most recent investment in this portfolio sample was in Noxilizer in 2025.
What sectors does NewVale Capital focus on?
NewVale Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech.
What company stages does NewVale Capital focus on?
NewVale Capital typically invests at the Mid stage.
What is NewVale Capital's AUM?
NewVale Capital's assets under management are estimated between $167.0M and $200.0M.